Bioequivalence of Highly Variable Drugs: A Comparison of the Newly Proposed Regulatory Approaches by FDA and EMAVangelis Karalis, Panos Macheras, Mira Symillides|Pharmaceutical Research|2011Cited by 68
Novel Scaled Average Bioequivalence Limits Based on GMR and Variability ConsiderationsVangelis Karalis, Panos Macheras, Mira Symillides|Pharmaceutical Research|2004Cited by 32
Geometric mean ratio-dependent scaled bioequivalence limits with leveling-off propertiesVangelis Karalis, Mira Symillides, Panos Macheras|European Journal of Pharmaceutical Sciences|2005Cited by 31
Novel Scaled Bioequivalence Limits with Leveling-off PropertiesJohn Kytariolos, Mira Symillides, Panos Macheras et al.|Pharmaceutical Research|2006Cited by 30